Extended Data Fig. 1: Patient responses and correlative data.

a, Flow cytometric measurable residual disease (MRD) in bone marrow aspirates using the different-from-normal (DfN) method. b, Copy number of CAR-123 per microgram of genomic DNA as measured by qPCR at indicated time points for each patient. c, Flow cytometry quantification of surface CD123 molecules on AML blasts of each patient (using “difference from normal” approach) at the indicated time points. d, Serial serum cytokine levels as measured serially in subjects on study via clinical Luminex panel. Data presented in log scale, normalized to the first time point ( ~ 1 week prior to initiation of LD chemo). Light red lines represent values from individual subjects, dark red line represents the mean of all patients at each time point for which >1 patient had a detectable value. e, IL-3 ELISA to complement Olink data, comparing clinical subjects’ baseline serum IL-3 level to “peak” IL-3 level. Statistical analysis performed using Welch’s two-tailed t-test.